The company announces that the first patient has been enrolled in study evaluating the efficacy of digital therapeutic modia in combination with sublingual buprenorphine/ naloxone for the treatment of opioid use disorder.
The randomized, open-label, parallel-group study will evaluate whether the use of modia in combination with sublingual buprenorphine/naloxone background therapy is superior to sublingual buprenorphine/naloxone alone to reduce illicit opioid use. The study is designed to enroll an estimated 400 participants at 35 sites across the US who are voluntarily seeking treatment for documented moderate to severe OUD.
“The enrollment of our first patient in the study of modia is a significant milestone toward closing that treatment gap and allowing more people easy access to a tool designed to support them in the battle against addiction.”
“When it comes to treating OUD, research has proven time and time again that we need to take a whole-person approach by addressing both the physical withdrawal symptoms and the mental health issues associated with addiction,” says Nikolaj Sørensen, President and CEO, Orexo. “Yet, all too often, the resources needed to effectively do so just aren’t available. The enrollment of our first patient in the study of modia is a significant milestone toward closing that treatment gap and allowing more people easy access to a tool designed to support them in the battle against addiction.”
Read more: Interview Nikolaj Sørensen
A patient perspective
modia has been co-developed with GAIA. In addition to GAIA’s research experience and Orexo’s expertise in OUD, patients with OUD were also included in the development and initial product testing of modia, offering a patient perspective that drives the therapeutic experience.
Photo of Nikolaj Sørensen: Orexo